ClinicalTrials.gg
CompletedNCT02098460Updated Mar 27, 2025

To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject

A Phase 4 interventional study of Atorvastatin, Probucol, Cilostazol in Severe Hypercholesterolemia, sponsored by Otsuka Beijing Research Institute. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by Otsuka Beijing Research Institute (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Enrollment
28th of 75
300 · median 148
Started
2013
with 3 others
Phase 4
28 of 77
1 open now
Registered
58th of 77
by date

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 28th largest by enrollment of the 75 interventional ones that give a count, is one of 4 that started in 2013, is one of 28 in phase 4, and was the 58th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

To evaluate the effect of concomitant administration of Probucol and Cilostazol (based on Atorvastatin treatment) on the atherosclerosis related markers (including the thickness of the Achilles tendon) in severe hypercholesterolemia subject, through the observation of the thickness of the Achilles tendon, the thickness of mean carotid intima-media, anti-oxidation biomarkers and serum lipid profile.

Read the detailed description

Multicenter, randomized, controlled, single-blinded, three parallel arms study. Group A: Atorvastatin + Probucol-placebo + Cilostazol-placebo Group B: Atorvastatin + Probucol + Cilostazol-placebo Group C: Atorvastatin + Probucol + Cilostazol

03

Conditions studied

  • Severe Hypercholesterolemia

Keywords

  • the Achilles tendon
  • intima-media thickness
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject whose voluntary written is obtained for participation in this study;
  2. 18≤age≤70;
  3. The subject with low-density lipoprotein cholesterol (LDL-C) ≥ 4.66 mmol/L (180 mg/dL) (the highest level either pre-treatment or on treatment);
  4. The subject with ATT≥9mm.

Exclusion criteria

Exclusion Criteria:

  1. The subject with homozygous familial hyperlipidemia;
  2. The subject who took Probucol within 6 months before the screening test;
  3. The subject who took Cilostazol within 1 month before the screening test;
  4. The subject who took Ezetimibe within 1 month before the screening test;
  5. The subject who hoped to treat with Ezetimibe within this study period;
  6. The subject being treated with Cyclosporine;
  7. The subject with a history of to Probucol and Cilostazol;
  8. The subject with a triglyceride (TG) level greater than 4.52 mmol/L (400 mg/dL);
  9. The subject with diabetes: level greater than 8.4% (NGSP);
  10. The subject with (NYHA) classification: Class III and IV;
  11. The subject with a greater than 450 msec (male) or 470 msec (female);
  12. The subject with serious ventricular arrythmias (frequent episodes of multifocal ventricular extrasystole);
  13. The subject with atrial fibrillation (including paroxysmal atrial fibrillation);
  14. The subject with congestive cardiac failure or unstable angina;
  15. The subject with liver and renal functions that satisfy the following criteria within 28 days prior to start of the medicinal product (IMP) administration.

    • ≥100 IU/L, ALT≥100 IU/L
    • Serum creatinine ≥1.5 mg/dL (133 µmol/L)
  16. The subject who are participating in another clinical trial;
  17. Woman during pregnancy or potential pregnancy, and breastfeeding;
  18. Women of who are not agree to use an appropriate method of ;
  19. The subject who are not considered by the Investigators to be appropriate to participate in this study for any other reasons.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Placebo comparator
    Probucol,Cilostazol

    Atorvastatin + Probucol-placebo + Cilostazol-placebo

    Drug: Atorvastatin, Probucol, Cilostazol

  • Placebo comparator
    Cilostazol

    Atorvastatin + Probucol+ Cilostazol-placebo

    Drug: Atorvastatin, Probucol, Cilostazol

  • Active comparator
    Probucol, Cilostazol

    Atorvastatin + Probucol + Cilostazol

    Drug: Atorvastatin, Probucol, Cilostazol

Interventions

06

What researchers measure

Primary outcomes

  1. the effect of concomitant administration of Probucol and Cilostazol on the mean achilles tendon thickness (ATT)

    Time frame: at Month 6, 12 and 24

Secondary outcomes

  1. the additional effect of concomitant administration of Probucol and Cilostazol on mean carotid intima-media thickness (IMT)

    Time frame: at Month 12 and 24

  2. the preventive effect of concomitant administration of Probucol and Cilostazol on the incidence of cerebrovascular and cardiovascular events (including intervention)

    Time frame: 2 years

  3. the effect of concomitant administration of Probucol and Cilostazol on biomarkers

    Time frame: 2 years

  4. the safety of Probucol or concomitant administration of Probucol and Cilostazol as determined by physical examination, vital signs, adverse events (AEs), laboratory examinations and 12-lead electrocardiogram (ECGs)

    Time frame: 2 years

07

Study locations

1 site
  • Anzhen hospital
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2014
First posted
Mar 28, 2014
Start
Oct 2013
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Last update
Mar 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02098460
Responsible party
Sponsor
First posted
Mar 28, 2014
Start date
Oct 2013
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Mar 27, 2025

Study contacts

Jie Lin, Dr
principal investigator · Anzhen hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Probucol · Cilostazol

Start the discussion